A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma

Cancer Immunity

Volumn 7, Issue , 2007, Pages

  Davis, Ian D ^a,b   Wiseman, Gregory A ^c   Lee, Fook Thean ^a   Gansen, Denise N ^c   Hopkins, Wendie ^a   Papenfuss, Anthony T ^d   Liu, Zhanqi ^a   Moynihan, Timothy J ^c   Croghan, Gary A ^c   Adjei, Alex A ^c   Hoffman, Eric W ^e   Ingle, James N ^c   Old, Lloyd J ^e   Scott, Andrew M ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c MAYO CLINIC   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

cG250; Chimeric antibody; Human CA9 protein; Phase I clinical trial; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BRAIN METASTASIS; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; RIGOR; SCINTILLATION CAMERA; TREATMENT RESPONSE; TUMOR LOCALIZATION; VOMITING; XEROSTOMIA;

EID: 34548083337     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statis-tics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-1623.
3. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-1095.
4. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
8. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Hor-vath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811.
9. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-746.
10. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, Warnaar SO. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-494.
11. Oosterwijk E, Bender NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, Old LJ. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-750.
12. Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oost-erwijk E. Strict regulation of CAIX (G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 23: 5624-5631.
13. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-3721.
14. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-2739.
15. Oosterwijk E, Divgi CR, Brouwers A, Boerman OC, Larson SM, Mulders P, Old LJ. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 2003; 30: 623-631.
16. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996; 19: 184-191.
17. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Antirenal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51: 171-177.
18. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-1537.
19. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5(10 Suppl): 3268s-3274s.
20. Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 2003; 49: 74-77.
21. Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 1412-1421.
22. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 985-990.
23. Neville N, Bevan P, Klöpfer P, Mala C, Hofmann R, Kindler M, Siebels M, Oberneder R. Treatment with monoclonal antibody cG250 (Rencarex®) in combination with IFNα-2a significantly prolongs survival in patients with metastatic renal cell cancer patients. 5th Kidney Cancer Symposium 2006; September 22-23; Chicago (IL).
24. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-310.
25. Hendrickx BW, Punt CJ, Boerman OC, Postema EJ, Oosterwijk E, Mavridu A, Corstens FH, Oyen WJ. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biother Radiopharm 2006; 21: 263-268.
26. Wiseman GA, Scott AM, Lee FT, Gansen W, Hopkins W, Steinmetz S, Ingle JN, Croghan GA, Burch PA, Davis I, Moynihan TJ, Warnaar S, Ullrich S, Mason JV, Pugliese L, Divgi CR, Hoffman EW, Old LJ. Chimeric G250 (cG250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2001; May 12-15; San Francisco (CA); 257a. Abstract 1027.
27. Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 6540-6548.
28. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-1271.
29. Bevan P, Mala C, Kindler M, Siebels M, Oberneder R, Beck HJ. Results of a phase I/II study with monoclonal antibody CG250 in combination with IFN α-2a in metastatic renal cell carcinoma patients. J Clin Oncol 2004; 22(14S): 4606.
30. WILEX AG - Pipeline. Accessed 18 July 2007. URL: http://www.wilex.com/R&D/Pipeline.htm
31. Al-Batran SE, Neumann A, Atmaca A, Ruppert M, Karbach J, Ritter G, Hoffman E, Old L, Knuth A, Jaeger E. LUD01-014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC). J Clin Oncol 2004; 22(14S): 2531.
32. Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res 2005; 11: 7178s-7186s.
33. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: an intrapatient comparison. Clin Cancer Res 2003; 9: 3953s-3960s.
34. Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 2003; 18: 525-533.
35. Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 14. URL: http://www.cancerimmunity.org/v7p14/070714.htm
36. Uemura H, Beniers AJ, Okajima E, Debruyne FM, Oosterwijk E. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int J Cancer 1994; 58: 555-561.